Wimmer Associates 1’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.02M | Buy |
8,575
+151
| +2% | +$53.8K | 1.47% | 17 |
|
|
2025
Q4 | $2.76M | Sell |
8,424
-43
| -0.5% | -$13.6K | 1.28% | 19 |
|
|
2025
Q3 | $2.39M | Sell |
8,467
-70
| -0.8% | -$20.3K | 1.15% | 22 |
|
|
2025
Q2 | $2.38M | Buy |
8,537
+44
| +0.5% | +$12.5K | 1.22% | 22 |
|
|
2025
Q1 | $2.3M | Sell |
8,493
-257
| -3% | -$75.9K | 1.21% | 24 |
|
|
2024
Q4 | $2.28M | Sell |
8,750
-385
| -4% | -$114K | 1.13% | 26 |
|
|
2024
Q3 | $2.94M | Sell |
9,135
-25
| -0.3% | -$8.18K | 1.44% | 18 |
|
|
2024
Q2 | $2.86M | Hold |
9,160
| – | – | 1.47% | 17 |
|
|
2024
Q1 | $2.6M | Buy |
9,160
+15
| +0.2% | +$4.39K | 1.37% | 21 |
|
|
2023
Q4 | $2.63M | Sell |
9,145
-10
| -0.1% | -$2.73K | 1.49% | 19 |
|
|
2023
Q3 | $2.46M | Buy |
9,155
+278
| +3% | +$69.4K | 1.54% | 19 |
|
|
2023
Q2 | $1.97M | Hold |
8,877
| – | – | 1.19% | 26 |
|
|
2023
Q1 | $2.07M | Sell |
8,877
-341
| -4% | -$83.7K | 1.32% | 24 |
|
|
2022
Q4 | $2.42M | Buy |
9,218
+124
| +1% | +$33.2K | 1.6% | 21 |
|
|
2022
Q3 | $2.46M | Buy |
9,094
+105
| +1% | +$25.5K | 1.63% | 22 |
|
|
2022
Q2 | $2.19M | Buy |
8,989
+162
| +2% | +$39.7K | 1.43% | 24 |
|
|
2022
Q1 | $2.13M | Sell |
8,827
-89
| -1% | -$20.4K | 1.19% | 28 |
|
|
2021
Q4 | $2.01M | Buy |
8,916
+58
| +0.7% | +$12.2K | 1.08% | 30 |
|
|
2021
Q3 | $1.88M | Sell |
8,858
-189
| -2% | -$43.5K | 1.12% | 27 |
|
|
2021
Q2 | $2.21M | Buy |
9,047
+85
| +0.9% | +$20.9K | 1.29% | 23 |
|
|
2021
Q1 | $2.23M | Buy |
8,962
+136
| +2% | +$32.5K | 1.21% | 24 |
|
|
2020
Q4 | $2.03M | Sell |
8,826
-50
| -0.6% | -$11.5K | 1.21% | 23 |
|
|
2020
Q3 | $2.26M | Buy |
8,876
+345
| +4% | +$85.5K | 1.52% | 20 |
|
|
2020
Q2 | $2.03M | Sell |
8,531
-383
| -4% | -$87.4K | 1.58% | 20 |
|
|
2020
Q1 | $1.81M | Buy |
8,914
+604
| +7% | +$132K | 1.68% | 21 |
|
|
2019
Q4 | $2M | Buy |
8,310
+2
| +0% | +$441 | 1.6% | 22 |
|
|
2019
Q3 | $1.61M | Buy |
8,308
+286
| +4% | +$54.9K | 1.4% | 26 |
|
|
2019
Q2 | $1.48M | Buy |
8,022
+101
| +1% | +$18.1K | 1.29% | 27 |
|
|
2019
Q1 | $1.5M | Sell |
7,921
-14
| -0.2% | -$2.67K | 1.33% | 28 |
|
|
2018
Q4 | $1.54M | Buy |
7,935
+496
| +7% | +$96.8K | 1.53% | 26 |
|
|
2018
Q3 | $1.54M | Buy |
7,439
+1
| +0% | +$197 | 1.28% | 30 |
|
|
2018
Q2 | $1.37M | Buy |
7,438
+281
| +4% | +$49.7K | 1.22% | 34 |
|
|
2018
Q1 | $1.22M | Buy |
7,157
+341
| +5% | +$62.6K | 1.08% | 37 |
|
|
2017
Q4 | $1.19M | Buy |
6,816
+695
| +11% | +$123K | 1.07% | 36 |
|
|
2017
Q3 | $1.14M | Sell |
6,121
-154
| -2% | -$27.3K | 1.05% | 39 |
|
|
2017
Q2 | $1.08M | Sell |
6,275
-469
| -7% | -$76.3K | 1% | 41 |
|
|
2017
Q1 | $1.11M | Buy |
6,744
+411
| +6% | +$68.3K | 1.03% | 39 |
|
|
2016
Q4 | $926K | Buy |
6,333
+391
| +7% | +$58.8K | 0.86% | 45 |
|
|
2016
Q3 | $991K | Sell |
5,942
-670
| -10% | -$113K | 0.89% | 42 |
|
|
2016
Q2 | $1.01M | Buy |
6,612
+306
| +5% | +$47.6K | 0.9% | 41 |
|
|
2016
Q1 | $945K | Buy |
6,306
+965
| +18% | +$143K | 0.87% | 43 |
|
|
2015
Q4 | $867K | Buy |
+5,341
| New | +$840K | 0.91% | 43 |
|
Other funds holding AMGN
VCM
VPM
Wimmer Associates 1's AMGN Position: Q1 2026 in Review
Wimmer Associates 1 increased its Amgen (AMGN) stake by 1.8% in Q1 2026, buying an estimated $53.8K and bringing the position to 8,575 shares worth $3.02M. The position accounts for 1.47% of the portfolio, ranked #17.
Wimmer Associates 1 first reported a position in AMGN in Q4 2015 and has held it in 42 quarters since. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Wimmer Associates 1 held 8,575 shares of Amgen worth $3.02M as of Q1 2026.
- Wimmer Associates 1 bought 151 Amgen shares in Q1 2026, an estimated $53.8K.
- Amgen made up 1.47% of Wimmer Associates 1's portfolio in Q1 2026, its #17 holding.
- Wimmer Associates 1 first reported a position in Amgen in Q4 2015 and has held it in 42 quarters since.
- 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Wimmer Associates 1's 13F filing for Q1 2026, filed 15 May 2026.